FDA Grants Priority Review for Novartis' Fabhalta (Ipacopan Hydrochloride)
The FDA has granted priority review status for Novartis' NDA for Fabhalta, containing ipacopan hydrochloride.
Asset / Drug
Drug and asset intelligence for Fabhalta with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Complement Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.